| Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted THT Nguyen, J Guedj, X Anglaret, C Laouénan, V Madelain, AM Taburet, ... PLoS neglected tropical diseases 11 (2), e0005389, 2017 | 189 | 2017 |
| Population modeling of tumor growth curves and the reduced Gompertz model improve prediction of the age of experimental tumors C Vaghi, A Rodallec, R Fanciullino, J Ciccolini, JP Mochel, M Mastri, ... PLoS computational biology 16 (2), e1007178, 2020 | 152 | 2020 |
| Antiviral efficacy of favipiravir against Ebola virus: A translational study in cynomolgus macaques J Guedj, G Piorkowski, F Jacquot, V Madelain, THT Nguyen, A Rodallec, ... PLoS medicine 15 (3), e1002535, 2018 | 136 | 2018 |
| Beating the odds: efficacy and toxicity of dihydropyrimidine dehydrogenase‐driven adaptive dosing of 5‐FU in patients with digestive cancer M Launay, L Dahan, M Duval, A Rodallec, G Milano, M Duluc, B Lacarelle, ... British journal of clinical pharmacology 81 (1), 124-130, 2016 | 61 | 2016 |
| Pharmacokinetics variability: Why nanoparticles are not just magic-bullets in oncology A Rodallec, S Benzekry, B Lacarelle, J Ciccolini, R Fanciullino Critical reviews in oncology/hematology 129, 1-12, 2018 | 49 | 2018 |
| Turning cold tumors into hot tumors: harnessing the potential of tumor immunity using nanoparticles A Rodallec, G Sicard, R Fanciullino, S Benzekry, B Lacarelle, G Milano, ... Expert opinion on drug metabolism & toxicology 14 (11), 1139-1147, 2018 | 46 | 2018 |
| Docetaxel–trastuzumab stealth immunoliposome: development and in vitro proof of concept studies in breast cancer A Rodallec, JM Brunel, S Giacometti, H Maccario, F Correard, E Mas, ... International journal of Nanomedicine, 3451-3465, 2018 | 46 | 2018 |
| From 3D spheroids to tumor bearing mice: Efficacy and distribution studies of trastuzumab-docetaxel immunoliposome in breast cancer A Rodallec, G Sicard, S Giacometti, M Carré, B Pourroy, F Bouquet, ... International journal of nanomedicine, 6677-6688, 2018 | 38 | 2018 |
| Claramines: A New Class Of Broad‐Spectrum Antimicrobial Agents With Bimodal Activity M Blanchet, D Borselli, A Rodallec, F Peiretti, N Vidal, JM Bolla, ... ChemMedChem 13 (10), 1018-1027, 2018 | 31 | 2018 |
| Enhanced antisense oligonucleotide delivery using cationic liposomes grafted with trastuzumab: A proof-of-concept study in prostate cancer G Sicard, C Paris, S Giacometti, A Rodallec, J Ciccolini, P Rocchi, ... Pharmaceutics 12 (12), 1166, 2020 | 21 | 2020 |
| Seek and destroy: improving PK/PD profiles of anticancer agents with nanoparticles A Rodallec, R Fanciullino, B Lacarelle, J Ciccolini Expert review of clinical pharmacology 11 (6), 599-610, 2018 | 21 | 2018 |
| Prototyping trastuzumab docetaxel immunoliposomes with a new FCM-based method to quantify optimal antibody density on nanoparticles A Rodallec, C Franco, S Robert, G Sicard, S Giacometti, B Lacarelle, ... Scientific Reports 10 (1), 4147, 2020 | 18 | 2020 |
| Tumor uptake and associated greater efficacy of anti-Her2 immunoliposome does not rely on Her2 expression status: study of a docetaxel-trastuzumab immunoliposome on Her2+ … A Rodallec, G Sicard, S Giacometti, M Carre, T Maia, M Valette, F Bouquet, ... Anti-Cancer Drugs 31 (5), 463-472, 2020 | 17 | 2020 |
| Tumor growth monitoring in breast cancer xenografts: A good technique for a strong ethic A Rodallec, C Vaghi, J Ciccolini, R Fanciullino, S Benzekry Plos one 17 (9), e0274886, 2022 | 12 | 2022 |
| Tumor growth kinetics of human MDA-MB-231 cells transfected with dTomato lentivirus A Rodallec, S Giacometti, J Ciccolini, R Fanciullino Dec, 2019 | 10 | 2019 |
| Is there any room for pharmacometrics with immuno-oncology drugs? Input from the EORTC-PAMM course on preclinical and early-phase clinical pharmacology A Rodallec, R Fanciullino, S Benzekry, J Ciccolini, EORTC PAMM Group Anticancer Research 39 (7), 3419-3422, 2019 | 7 | 2019 |
| Upfront DPD Deficiency Detection to Secure 5-FU Administration: Part 1-Where Do We Stand? M Launay, J Ciccolini, A Rodallec, C Fournel, F Duffaud, S Salas, ... Clinical Cancer Drugs 4 (2), 74-81, 2017 | 6 | 2017 |
| Nanotherapeutics Plus Immunotherapy in Oncology: Who Brings What to the Table? E Timon-David, C Perez, A Rodallec Pharmaceutics 14 (11), 2326, 2022 | 3 | 2022 |
| Population modeling of tumor growth curves, the reduced Gompertz model and prediction of the age of a tumor C Vaghi, A Rodallec, R Fanciullino, J Ciccolini, J Mochel, M Mastri, ... Mathematical and Computational Oncology: First International Symposium …, 2019 | 3 | 2019 |
| Pegylated liposome encapsulating docetaxel using microfluidic mixing technique: Process optimization and results in breast cancer models M Dacos, B Immordino, E Diroff, G Sicard, A Kosta, A Rodallec, ... International Journal of Pharmaceutics 656, 124091, 2024 | 2 | 2024 |
